» Articles » PMID: 34359605

Systematic Roadmap for Cancer Drug Screening Using Zebrafish Embryo Xenograft Cancer Models: Melanoma Cell Line As a Case Study

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Aug 7
PMID 34359605
Authors
Affiliations
Soon will be listed here.
Abstract

Zebrafish embryo tumor transplant models are widely utilized in cancer research. Compared with traditional murine models, the small size and transparency of zebrafish embryos combined with large clutch sizes that increase statistical power and cheap husbandry make them a cost-effective and versatile tool for in vivo drug discovery. However, the lack of a comprehensive analysis of key factors impacting the successful use of these models impedes the establishment of basic guidelines for systematic screening campaigns. Thus, we explored the following crucial factors: (i) user-independent inclusion criteria, focusing on sample homogeneity; (ii) metric definition for data analysis; (iii) tumor engraftment criteria; (iv) image analysis versus quantification of human cancer cells using qPCR (RNA and gDNA); (v) tumor implantation sites; (vi) compound distribution (intratumoral administration versus alternative inoculation sites); and (vii) efficacy (intratumoral microinjection versus compound solution in media). Based on these analyses and corresponding assessments, we propose the first roadmap for systematic drug discovery screening in zebrafish xenograft cancer models using a melanoma cell line as a case study. This study aims to help the wider cancer research community to consider the adoption of this versatile model for cancer drug screening projects.

Citing Articles

Diverse Engraftment Capability of Neuroblastoma Cell Lines in Zebrafish Larvae.

Lawrence J, Tan S, Kim D, Tan K, Schroeder S, Yeo K Zebrafish. 2024; 21(6):385-393.

PMID: 39316469 PMC: 11876807. DOI: 10.1089/zeb.2024.0160.

References
1.
Farren M, Hennessey R, Shakya R, Elnaggar O, Young G, Kendra K . The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther. 2017; 16(3):417-427. PMC: 5407496. DOI: 10.1158/1535-7163.MCT-16-0498. View

2.
Avci M, Keskus A, Targen S, Isilak M, Ozturk M, Cetin Atalay R . Development of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines. Sci Rep. 2018; 8(1):1570. PMC: 5785479. DOI: 10.1038/s41598-018-19817-w. View

3.
Letrado P, de Miguel I, Lamberto I, Diez-Martinez R, Oyarzabal J . Zebrafish: Speeding Up the Cancer Drug Discovery Process. Cancer Res. 2018; 78(21):6048-6058. DOI: 10.1158/0008-5472.CAN-18-1029. View

4.
Zhang F, Qin W, Zhang J, Hu C . Antibiotic toxicity and absorption in zebrafish using liquid chromatography-tandem mass spectrometry. PLoS One. 2015; 10(5):e0124805. PMC: 4418659. DOI: 10.1371/journal.pone.0124805. View

5.
Ku M . Use of the Biopharmaceutical Classification System in early drug development. AAPS J. 2008; 10(1):208-12. PMC: 2751465. DOI: 10.1208/s12248-008-9020-0. View